<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636994</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-2715</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>The American journal of hospice &amp; palliative care</Title><ISOAbbreviation>Am J Hosp Palliat Care</ISOAbbreviation></Journal><ArticleTitle>Perceptions of Palliative Care Program Viability During the Pandemic: Qualitative Results From a National Survey.</ArticleTitle><Pagination><StartPage>10499091231152610</StartPage><MedlinePgn>10499091231152610</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/10499091231152610</ELocationID><Abstract><AbstractText><b>Background:</b> Palliative care programs have played a significant role during the COVID-19 pandemic. However, the financial impact of the pandemic and operational challenges for palliative care programs have raised concerns for their future viability. <b>Objectives:</b> To explore palliative care program leaders' perceptions of the future viability of their programs in the context of the pandemic and inform future educational and program development. <b>Methods:</b> Surveys were sent to 1430 specialist palliative care program leaders, identified through the Center to Advance Palliative Care's contact lists, via email in May 2020 and January 2021. Leaders were asked why they were or were not concerned about the viability of their palliative care programs. Qualitative content analysis was applied to determine themes. <b>Results:</b> We received 440 responses. Most programs served hospital settings and were geographically located across all US regions. We identified four themes: 1) The importance of being valued by organizational leadership and peers, 2) The importance of adequate and supported palliative care staff, 3) The pandemic validated and accelerated the need for palliative care, and 4) The pandemic perpetuated organizational financial concerns. <b>Conclusion:</b> Findings provide insights about palliative care program viability from the perspective of program leaders during a global pandemic. Technical assistance to support palliative care teams and their relationships with stakeholders, methods to measure the impact of peer support, efforts to educate administrators about the value of palliative care, and efforts to reduce burnout are needed to sustain palliative care programs into the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Maggie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0049-2987</Identifier><AffiliationInfo><Affiliation>Center to Advance Palliative Care at the Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heitner</LastName><ForeName>Rachael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center to Advance Palliative Care at the Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frydman</LastName><ForeName>Julia L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-0021-7627</Identifier><AffiliationInfo><Affiliation>Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowman</LastName><ForeName>Brynn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center to Advance Palliative Care at the Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>Diane E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Center to Advance Palliative Care at the Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldridge</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>20071James J. Peters VA Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzosa</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7590-0316</Identifier><AffiliationInfo><Affiliation>Brookdale Department of Geriatrics and Palliative Medicine, 5925Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>20071James J. Peters VA Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hosp Palliat Care</MedlineTA><NlmUniqueID>9008229</NlmUniqueID><ISSNLinking>1049-9091</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">burnout</Keyword><Keyword MajorTopicYN="N">palliative care</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">program design</Keyword><Keyword MajorTopicYN="N">workforce</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636994</ArticleId><ArticleId IdType="doi">10.1177/10499091231152610</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636983</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><PubDate><Year>2023</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>A Retrospective Population Study of 385 191 Positive Real-Time Reverse Transcription-Polymerase Chain Reaction Tests For SARS-CoV-2 from a Single Laboratory in Katowice, Poland from April 2020 to July 2022.</ArticleTitle><Pagination><StartPage>e938872</StartPage><MedlinePgn>e938872</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12659/MSM.938872</ELocationID><Abstract><AbstractText>BACKGROUND This retrospective population study identified 385 191 positive real-time reverse transcription-polymerase chain reaction (RT-PCR) tests for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a single laboratory in Katowice, Poland, from April 2020 to July 2022. MATERIAL AND METHODS The material was nasopharyngeal, nasopharyngeal swab or bronchial lavage, and bronchoalveolar lavage (BAL) to confirm or exclude SARS-CoV-2 infection with the RT-PCR technique. Personal data are use according to the Provisions on the Protection of Personal Data by the Gyn-Centrum laboratory. RESULTS In 9 months of 2020, the number of SARS-CoV-2 results was 88 986; in 2021, it was 168 439, and in the first 7 months of 2022, it was 12 786. In 2020, the highest number of positive results was recorded in the third quarter (83 094 cases); 2021, in the 1st, 2nd, and 4th quarters (58 712; 37 720; and 71 753 cases, respectively), and in 2022, in the 1st quarter (127 613 cases) of the year. A positive result was observed more often in women and people aged 30-39, followed by those 40-49 years. Patients aged 10-19 years comprised the smallest population of SARS-CoV-2-positive cases. CONCLUSIONS In the Polish population studied, from April 2020 to July 2022, the detection rates of SARS-CoV-2 positivity were significantly higher for women than for men and in the 30-49 age group for both sexes. Also, the infection detection rate of 385 191 out of 1 332 659 patient samples, or 28.9%, supports that the Polish society adhered to public health recommendations for infection control during the COVID-19 pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morawiec</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bednarska-Czerwi&#x144;ska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pude&#x142;ko</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Gyncentrum Fertility Clinic, Sosnowiec, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strychalska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Gyncentrum Fertility Clinic, Sosnowiec, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broncel</LastName><ForeName>Mateusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Gyncentrum Fertility Clinic, Sosnowiec, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagan</LastName><ForeName>Dorota</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical Center Dormed Medical SP, Busko-Zdr&#xf3;j, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madej</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jasi&#x144;ska-Balwierz</LastName><ForeName>Agata</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staszkiewicz</LastName><ForeName>Rafa&#x142;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soba&#x144;ski</LastName><ForeName>Dawid</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boro&#x144;</LastName><ForeName>Dariusz</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pokusa</LastName><ForeName>Filip</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Faculty of Economics and Pedagogy, Higher School of Management and Administration in Opole, Opole, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grabarek</LastName><ForeName>Beniamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Histology, Cytophysiology and Embryology, Academy of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636983</ArticleId><ArticleId IdType="doi">10.12659/MSM.938872</ArticleId><ArticleId IdType="pii">938872</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636979</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0022-9040</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Kardiologiia</Title><ISOAbbreviation>Kardiologiia</ISOAbbreviation></Journal><ArticleTitle>[Case of peripartum cardiomyopathy misdiagnosed as pulmonary changes due to COVID-19].</ArticleTitle><Pagination><StartPage>80</StartPage><EndPage>84</EndPage><MedlinePgn>80-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18087/cardio.2022.12.n1668</ELocationID><Abstract><AbstractText>A 37-year-old female patient was admitted 16 days after delivery in a hospital for infectious diseases with cough, shortness of breath, and infiltrative changes in the lungs that were interpreted as viral pneumonia. Considering the failure of therapy and the history, peripartum cardiomyopathy was suspected. Examination revealed a decrease in left ventricular ejection fraction to 30&#x200a;%, ultrasonic signs of lung congestion and bilateral hydrothorax. The patient was diagnosed with peripartum cardiomyopathy accompanied by functional class 4 heart failure. A specific feature of this case was fast positive dynamics with complete regression of the clinical picture of congestion and improvement of the left ventricular myocardial function associated with the treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gavrilov</LastName><ForeName>D V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>&#x41e;&#x41e;&#x41e; "K-Skay".</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagirova</LastName><ForeName>Z R</ForeName><Initials>ZR</Initials><AffiliationInfo><Affiliation>Emergency Care Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pleskatsevich</LastName><ForeName>D I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Emergency Care Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuznetsova</LastName><ForeName>O V</ForeName><Initials>OV</Initials><AffiliationInfo><Affiliation>Emergency Care Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivshin</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Petrozavodsk State Medical University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuznetsova</LastName><ForeName>T Yu</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Petrozavodsk State Medical University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Kardiologiia</MedlineTA><NlmUniqueID>0376351</NlmUniqueID><ISSNLinking>0022-9040</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636979</ArticleId><ArticleId IdType="doi">10.18087/cardio.2022.12.n1668</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636975</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0022-9040</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Kardiologiia</Title><ISOAbbreviation>Kardiologiia</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>38</StartPage><EndPage>49</EndPage><MedlinePgn>38-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18087/cardio.2022.12.n2125</ELocationID><Abstract><AbstractText>&#x426;&#x435;&#x43b;&#x44c;:&#xa0;&#xa0;&#x418;&#x437;&#x443;&#x447;&#x435;&#x43d;&#x438;&#x435; &#x43e;&#x441;&#x43e;&#x431;&#x435;&#x43d;&#x43d;&#x43e;&#x441;&#x442;&#x435;&#x439; &#x43a;&#x43b;&#x438;&#x43d;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x433;&#x43e; &#x442;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44f; &#x43d;&#x43e;&#x432;&#x43e;&#x439; &#x43a;&#x43e;&#x440;&#x43e;&#x43d;&#x430;&#x432;&#x438;&#x440;&#x443;&#x441;&#x43d;&#x43e;&#x439; &#x438;&#x43d;&#x444;&#x435;&#x43a;&#x446;&#x438;&#x438; &#x438;&#xa0; &#x432;&#x43b;&#x438;&#x44f;&#x43d;&#x438;&#x44f; &#x441;&#x43e;&#x43f;&#x443;&#x442;&#x441;&#x442;&#x432;&#x443;&#x44e;&#x449;&#x438;&#x445; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x43d;&#x430; &#x438;&#x441;&#x445;&#x43e;&#x434; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x44f; &#x443; &#x433;&#x43e;&#x441;&#x43f;&#x438;&#x442;&#x430;&#x43b;&#x438;&#x437;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x43d;&#x44b;&#x445; &#x431;&#x43e;&#x43b;&#x44c;&#x43d;&#x44b;&#x445; &#x441; &#x438;&#x43d;&#x444;&#x435;&#x43a;&#x446;&#x438;&#x435;&#x439; SARS-CoV-2 &#x432; &#x43f;&#x435;&#x440;&#x432;&#x443;&#x44e; &#x438; &#x432;&#x442;&#x43e;&#x440;&#x443;&#x44e; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438;.&#x41c;&#x435;&#x442;&#x43e;&#x434;&#x44b; &#x438; &#x440;&#x435;&#x437;&#x443;&#x43b;&#x44c;&#x442;&#x430;&#x442;&#x44b;.&#xa0; &#x414;&#x43b;&#x44f; &#x43e;&#x446;&#x435;&#x43d;&#x43a;&#x438; &#x43e;&#x441;&#x43e;&#x431;&#x435;&#x43d;&#x43d;&#x43e;&#x441;&#x442;&#x435;&#x439; &#x442;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44f; COVID-19 &#x432; &#x415;&#x432;&#x440;&#x430;&#x437;&#x438;&#x439;&#x441;&#x43a;&#x43e;&#x43c; &#x440;&#x435;&#x433;&#x438;&#x43e;&#x43d;&#x435; &#x431;&#x44b;&#x43b;&#x438; &#x441;&#x43e;&#x437;&#x434;&#x430;&#x43d;&#x44b; &#x43c;&#x435;&#x436;&#x434;&#x443;&#x43d;&#x430;&#x440;&#x43e;&#x434;&#x43d;&#x44b;&#x435; &#x440;&#x435;&#x433;&#x438;&#x441;&#x442;&#x440;&#x44b; &#x410;&#x41a;&#x422;&#x418;&#x412; 1 &#x438; &#x432;&#x43e; &#x432;&#x440;&#x435;&#x43c;&#x44f; &#x432;&#x442;&#x43e;&#x440;&#x43e;&#x439; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x410;&#x41a;&#x422;&#x418;&#x412; 2. &#x41d;&#x430;&#x431;&#x43e;&#x440; &#x431;&#x43e;&#x43b;&#x44c;&#x43d;&#x44b;&#x445; &#x432; &#x440;&#x435;&#x433;&#x438;&#x441;&#x442;&#x440; &#x410;&#x41a;&#x422;&#x418;&#x412; 1 &#x43f;&#x440;&#x43e;&#x432;&#x43e;&#x434;&#x438;&#x43b;&#x438; &#x441; 29.06.20 &#x43f;&#x43e; 29.10.20, &#x43d;&#x430;&#x431;&#x440;&#x430;&#x43d;&#x43e; 5 397 &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432;. &#x41f;&#x440;&#x438;&#x435;&#x43c; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x43d;&#x430; &#x443;&#x447;&#x435;&#x442; &#x432; &#x410;&#x41a;&#x422;&#x418;&#x412; 2 &#x43f;&#x440;&#x43e;&#x432;&#x43e;&#x434;&#x438;&#x43b;&#x438; &#x441; 01.11.20 &#x434;&#x43e; 30.03.21, &#x43d;&#x430;&#x431;&#x440;&#x430;&#x43d;&#x43e; 2 665 &#x431;&#x43e;&#x43b;&#x44c;&#x43d;&#x44b;&#x445;.&#x420;&#x435;&#x437;&#x443;&#x43b;&#x44c;&#x442;&#x430;&#x442;&#x44b;. &#x413;&#x43e;&#x441;&#x43f;&#x438;&#x442;&#x430;&#x43b;&#x44c;&#x43d;&#x430;&#x44f; &#x43b;&#x435;&#x442;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x441;&#x43d;&#x438;&#x437;&#x438;&#x43b;&#x430;&#x441;&#x44c; &#x432; &#xa0;&#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434; &#x432;&#x442;&#x43e;&#x440;&#x43e;&#x439; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x438; &#xa0;&#x441;&#x43e;&#x441;&#x442;&#x430;&#x432;&#x438;&#x43b;&#x430; 4,8 % &#x43f;&#x440;&#x43e;&#x442;&#x438;&#x432; 7,6 % &#x432; &#xa0;&#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434; &#x43f;&#x435;&#x440;&#x432;&#x43e;&#x439; &#x432;&#x43e;&#x43b;&#x43d;&#x44b;. &#x412; &#xa0;&#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434; &#x432;&#x442;&#x43e;&#x440;&#x43e;&#x439; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x44b; &#x431;&#x44b;&#x43b;&#x438; &#x441;&#x442;&#x430;&#x440;&#x448;&#x435;, &#x438;&#x43c;&#x435;&#x43b;&#x438; &#x431;&#x43e;&#x43b;&#x44c;&#x448;&#x435; &#x441;&#x43e;&#x43f;&#x443;&#x442;&#x441;&#x442;&#x432;&#x443;&#x44e;&#x449;&#x438;&#x445; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x438; &#x43f;&#x43e;&#x441;&#x442;&#x443;&#x43f;&#x430;&#x43b;&#x438; &#x432; &#x441;&#x442;&#x430;&#x446;&#x438;&#x43e;&#x43d;&#x430;&#x440; &#x432; &#x431;&#x43e;&#x43b;&#x435;&#x435; &#x442;&#x44f;&#x436;&#x435;&#x43b;&#x43e;&#x43c; &#x441;&#x43e;&#x441;&#x442;&#x43e;&#x44f;&#x43d;&#x438;&#x438;, &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x44b; &#x438;&#x43c;&#x435;&#x43b;&#x438; &#x431;&#x43e;&#x43b;&#x435;&#x435; &#x432;&#x44b;&#x441;&#x43e;&#x43a;&#x438;&#x439; &#x443;&#x440;&#x43e;&#x432;&#x435;&#x43d;&#x44c; &#x43f;&#x43e;&#x43b;&#x438;&#x43c;&#x43e;&#x440;&#x431;&#x438;&#x434;&#x43d;&#x43e;&#x441;&#x442;&#x438;. &#x412; &#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434; &#x432;&#x442;&#x43e;&#x440;&#x43e;&#x439; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x443;&#x432;&#x435;&#x43b;&#x438;&#x447;&#x438;&#x43b;&#x430;&#x441;&#x44c; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x435;&#x43c;&#x43e;&#x441;&#x442;&#x44c; &#x431;&#x430;&#x43a;&#x442;&#x435;&#x440;&#x438;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x439; &#x43f;&#x43d;&#x435;&#x432;&#x43c;&#x43e;&#x43d;&#x438;&#x435;&#x439; &#x438; &#x441;&#x435;&#x43f;&#x441;&#x438;&#x441;&#x43e;&#x43c;, &#x43d;&#x43e; &#x440;&#x435;&#x436;&#x435; &#x432;&#x441;&#x442;&#x440;&#x435;&#x447;&#x430;&#x43b;&#x438;&#x441;&#x44c; &#x442;&#x440;&#x43e;&#x43c;&#x431;&#x43e;&#x437;&#x44b; &#x433;&#x43b;&#x443;&#x431;&#x43e;&#x43a;&#x438;&#x445; &#x432;&#x435;&#x43d; &#x438; &#xab;&#x446;&#x438;&#x442;&#x43e;&#x43a;&#x438;&#x43d;&#x43e;&#x432;&#x44b;&#x439; &#x448;&#x442;&#x43e;&#x440;&#x43c;&#xbb;. &#x41d;&#x430;&#x438;&#x431;&#x43e;&#x43b;&#x435;&#x435; &#x43d;&#x435;&#x431;&#x43b;&#x430;&#x433;&#x43e;&#x43f;&#x440;&#x438;&#x44f;&#x442;&#x43d;&#x44b;&#x43c;&#x438; &#x434;&#x43b;&#x44f; &#x43f;&#x440;&#x43e;&#x433;&#x43d;&#x43e;&#x437;&#x430; &#x441;&#x43c;&#x435;&#x440;&#x442;&#x43d;&#x43e;&#x441;&#x442;&#x438;, &#x43a;&#x430;&#x43a; &#x432; &#x43f;&#x435;&#x440;&#x432;&#x443;&#x44e;, &#x442;&#x430;&#x43a; &#x438; &#x432;&#x43e; &#x432;&#x442;&#x43e;&#x440;&#x443;&#x44e; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x44d;&#x43f;&#x438;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x431;&#x44b;&#x43b;&#x438; &#x441;&#x43e;&#x447;&#x435;&#x442;&#x430;&#x43d;&#x438;&#x44f; &#x441;&#x43e;&#x43f;&#x443;&#x442;&#x441;&#x442;&#x432;&#x443;&#x44e;&#x449;&#x438;&#x445; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x439;: &#x430;&#x440;&#x442;&#x435;&#x440;&#x438;&#x430;&#x43b;&#x44c;&#x43d;&#x430;&#x44f; &#x433;&#x438;&#x43f;&#x435;&#x440;&#x442;&#x435;&#x43d;&#x437;&#x438;&#x44f; (&#x410;&#x413;) + &#x445;&#x440;&#x43e;&#x43d;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x430;&#x44f; &#x441;&#x435;&#x440;&#x434;&#x435;&#x447;&#x43d;&#x430;&#x44f; &#x43d;&#x435;&#x434;&#x43e;&#x441;&#x442;&#x430;&#x442;&#x43e;&#x447;&#x43d;&#x43e;&#x441;&#x442;&#x44c; (&#x425;&#x421;&#x41d;) + &#x441;&#x430;&#x445;&#x430;&#x440;&#x43d;&#x44b;&#x439; &#x434;&#x438;&#x430;&#x431;&#x435;&#x442; (&#x421;&#x414;) + &#x43e;&#x436;&#x438;&#x440;&#x435;&#x43d;&#x438;&#x435;, &#x410;&#x413; + &#x438;&#x448;&#x435;&#x43c;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x430;&#x44f; &#x431;&#x43e;&#x43b;&#x435;&#x437;&#x43d;&#x44c; &#x441;&#x435;&#x440;&#x434;&#x446;&#x430; (&#x418;&#x411;&#x421;) + &#x425;&#x421;&#x41d; + &#x421;&#x414;, &#x410;&#x413; + &#x418;&#x411;&#x421; + &#x425;&#x421;&#x41d; + &#x43e;&#x436;&#x438;&#x440;&#x435;&#x43d;&#x438;&#x435;.&#x417;&#x430;&#x43a;&#x43b;&#x44e;&#x447;&#x435;&#x43d;&#x438;&#x435;.&#xa0;&#x423; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x432;&#x43e; &#x432;&#x442;&#x43e;&#x440;&#x443;&#x44e; &#x432;&#x43e;&#x43b;&#x43d;&#x443; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x43d;&#x430;&#x431;&#x43b;&#x44e;&#x434;&#x430;&#x43b;&#x43e;&#x441;&#x44c; &#x431;&#x43e;&#x43b;&#x435;&#x435; &#x43e;&#x431;&#x448;&#x438;&#x440;&#x43d;&#x43e;&#x435; &#x43f;&#x43e;&#x440;&#x430;&#x436;&#x435;&#x43d;&#x438;&#x435; &#x442;&#x43a;&#x430;&#x43d;&#x438; &#x43b;&#x435;&#x433;&#x43a;&#x438;&#x445;, &#x447;&#x430;&#x449;&#x435; &#x432;&#x43e;&#x437;&#x43d;&#x438;&#x43a;&#x430;&#x43b;&#x430; &#x444;&#x435;&#x431;&#x440;&#x438;&#x43b;&#x44c;&#x43d;&#x430;&#x44f; &#x43b;&#x438;&#x445;&#x43e;&#x440;&#x430;&#x434;&#x43a;&#x430;, &#x431;&#x44b;&#x43b;&#x438; &#x432;&#x44b;&#x448;&#x435; &#x443;&#x440;&#x43e;&#x432;&#x43d;&#x438; &#x421;-&#x440;&#x435;&#x430;&#x43a;&#x442;&#x438;&#x432;&#x43d;&#x43e;&#x433;&#x43e; &#x431;&#x435;&#x43b;&#x43a;&#x430; &#x438; &#xa0;&#x442;&#x440;&#x43e;&#x43f;&#x43e;&#x43d;&#x438;&#x43d;&#x430;, &#x43d;&#x438;&#x436;&#x435; &#x443;&#x440;&#x43e;&#x432;&#x43d;&#x438; &#x433;&#x435;&#x43c;&#x43e;&#x433;&#x43b;&#x43e;&#x431;&#x438;&#x43d;&#x430; &#x438; &#x43b;&#x438;&#x43c;&#x444;&#x43e;&#x446;&#x438;&#x442;&#x43e;&#x432;. &#x42d;&#x442;&#x43e;, &#x432;&#x435;&#x440;&#x43e;&#x44f;&#x442;&#x43d;&#x43e;, &#x441;&#x432;&#x44f;&#x437;&#x430;&#x43d;&#x43e; &#x441; &#x440;&#x430;&#x437;&#x43b;&#x438;&#x447;&#x43d;&#x43e;&#x439; &#x442;&#x430;&#x43a;&#x442;&#x438;&#x43a;&#x43e;&#x439; &#x433;&#x43e;&#x441;&#x43f;&#x438;&#x442;&#x430;&#x43b;&#x438;&#x437;&#x430;&#x446;&#x438;&#x438; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x432; &#x43f;&#x435;&#x440;&#x432;&#x443;&#x44e; &#x438; &#x432;&#x442;&#x43e;&#x440;&#x443;&#x44e; &#x432;&#x43e;&#x43b;&#x43d;&#x44b; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x432; &#x441;&#x442;&#x440;&#x430;&#x43d;&#x430;&#x445;, &#x43f;&#x440;&#x438;&#x43d;&#x44f;&#x432;&#x448;&#x438;&#x445; &#x443;&#x447;&#x430;&#x441;&#x442;&#x438;&#x435; &#x432; &#x444;&#x43e;&#x440;&#x43c;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x438; &#x440;&#x435;&#x433;&#x438;&#x441;&#x442;&#x440;&#x43e;&#x432; &#x410;&#x41a;&#x422;&#x418;&#x412; 1 &#x438; &#x410;&#x41a;&#x422;&#x418;&#x412; 2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arutyunov</LastName><ForeName>Gregory Pavlovich</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>&#x424;&#x413;&#x410;&#x41e;&#x423; &#x412;&#x41e; &#xab;&#x420;&#x41d;&#x418;&#x41c;&#x423; &#x438;&#x43c;. &#x41d;.&#x418;. &#x41f;&#x438;&#x440;&#x43e;&#x433;&#x43e;&#x432;&#x430;&#xbb;, &#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; "&#x415;&#x432;&#x440;&#x430;&#x437;&#x438;&#x439;&#x441;&#x43a;&#x430;&#x44f; &#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; &#x422;&#x435;&#x440;&#x430;&#x43f;&#x435;&#x432;&#x442;&#x43e;&#x432;".</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarlovskaya</LastName><ForeName>Ekaterina Iosifovna</ForeName><Initials>EI</Initials><AffiliationInfo><Affiliation>&#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; "&#x415;&#x432;&#x440;&#x430;&#x437;&#x438;&#x439;&#x441;&#x43a;&#x430;&#x44f; &#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; &#x422;&#x435;&#x440;&#x430;&#x43f;&#x435;&#x432;&#x442;&#x43e;&#x432;", &#x424;&#x413;&#x411;&#x41e;&#x423; &#x412;&#x41e; &#x41f;&#x418;&#x41c;&#x423; &#x41c;&#x417; &#x420;&#x424;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arutyunov</LastName><ForeName>Alexander Grigorievich</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>&#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; "&#x415;&#x432;&#x440;&#x430;&#x437;&#x438;&#x439;&#x441;&#x43a;&#x430;&#x44f; &#x410;&#x441;&#x441;&#x43e;&#x446;&#x438;&#x430;&#x446;&#x438;&#x44f; &#x422;&#x435;&#x440;&#x430;&#x43f;&#x435;&#x432;&#x442;&#x43e;&#x432;", &#x424;&#x413;&#x410;&#x41e;&#x423; &#x412;&#x41e; &#xab;&#x420;&#x41d;&#x418;&#x41c;&#x423; &#x438;&#x43c;. &#x41d;.&#x418;. &#x41f;&#x438;&#x440;&#x43e;&#x433;&#x43e;&#x432;&#x430;&#xbb;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belenkov</LastName><ForeName>Yuri Nikitich</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>&#x424;&#x413;&#x410;&#x41e;&#x423; &#x412;&#x41e; &#x41f;&#x435;&#x440;&#x432;&#x44b;&#x439; &#x41c;&#x413;&#x41c;&#x423; &#x438;&#x43c; &#x418;.&#x41c;. &#x421;&#x435;&#x447;&#x435;&#x43d;&#x43e;&#x432;&#x430; &#x41c;&#x438;&#x43d;&#x437;&#x434;&#x440;&#x430;&#x432;&#x430; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x438;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konradi</LastName><ForeName>Alexandra Olegovna</ForeName><Initials>AO</Initials><AffiliationInfo><Affiliation>&#x424;&#x413;&#x411;&#x423; &#xab;&#x41d;&#x430;&#x446;&#x438;&#x43e;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x44b;&#x439; &#x43c;&#x435;&#x434;&#x438;&#x446;&#x438;&#x43d;&#x441;&#x43a;&#x438;&#x439; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x442;&#x435;&#x43b;&#x44c;&#x441;&#x43a;&#x438;&#x439; &#x446;&#x435;&#x43d;&#x442;&#x440; &#x438;&#x43c;. &#x412;. &#x410;. &#x410;&#x43b;&#x43c;&#x430;&#x437;&#x43e;&#x432;&#x430;&#xbb; &#x41c;&#x438;&#x43d;&#x437;&#x434;&#x440;&#x430;&#x432;&#x430; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x438;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopatin</LastName><ForeName>Yury Mikhailovich</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>&#x424;&#x413;&#x411;&#x41e;&#x423; &#x412;&#x41e; &#x412;&#x43e;&#x43b;&#x433;&#x413;&#x41c;&#x423; &#x41c;&#x438;&#x43d;&#x437;&#x434;&#x440;&#x430;&#x432;&#x430; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x438;.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>&#x410;&#x43d;&#x430;&#x43b;&#x438;&#x437; &#x432;&#x43b;&#x438;&#x44f;&#x43d;&#x438;&#x44f; &#x43a;&#x43e;&#x43c;&#x43e;&#x440;&#x431;&#x438;&#x434;&#x43d;&#x43e;&#x439; &#x441;&#x435;&#x440;&#x434;&#x435;&#x447;&#x43d;&#x43e;-&#x441;&#x43e;&#x441;&#x443;&#x434;&#x438;&#x441;&#x442;&#x43e;&#x439; &#x43f;&#x430;&#x442;&#x43e;&#x43b;&#x43e;&#x433;&#x438;&#x438; &#x43d;&#x430; &#x442;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x435; &#x438; &#x438;&#x441;&#x445;&#x43e;&#x434;&#x44b; COVID-19 &#x443; &#x433;&#x43e;&#x441;&#x43f;&#x438;&#x442;&#x430;&#x43b;&#x438;&#x437;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x43d;&#x44b;&#x445; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x432; &#x43f;&#x435;&#x440;&#x432;&#x443;&#x44e; &#x438; &#x432;&#x442;&#x43e;&#x440;&#x443;&#x44e; &#x432;&#x43e;&#x43b;&#x43d;&#x443; &#x43f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x438; &#x432; &#x415;&#x432;&#x440;&#x430;&#x437;&#x438;&#x439;&#x441;&#x43a;&#x43e;&#x43c; &#x440;&#x435;&#x433;&#x438;&#x43e;&#x43d;&#x435;.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Kardiologiia</MedlineTA><NlmUniqueID>0376351</NlmUniqueID><ISSNLinking>0022-9040</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636975</ArticleId><ArticleId IdType="doi">10.18087/cardio.2022.12.n2125</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636974</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0022-9040</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Kardiologiia</Title><ISOAbbreviation>Kardiologiia</ISOAbbreviation></Journal><ArticleTitle>Electrocardiogram QRS Complex Duration as a Predictor of Hospital Prognosis in Patients With COVID-19.</ArticleTitle><Pagination><StartPage>30</StartPage><EndPage>37</EndPage><MedlinePgn>30-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18087/cardio.2022.12.n2260</ELocationID><Abstract><AbstractText>Aim&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; To determine the effect of major electrocardiographic (ECG) parameters on the prognosis of patients with COVID-19.Material and methods&#xa0; One of systemic manifestations of COVID-19 is heart injury. ECG is the most simple and available method for diagnosing the heart injury, which influences the therapeutic approach. This study included 174 hospitalized patients with COVID-19. Major ECG parameters recorded on admission and their changes before the discharge from the hospital or death of the patient, were analyzed, and the effect of each parameter on the in-hospital prognosis was determined. Results were compared with the left ventricular ejection fraction (LV EF), laboratory data, and results of multispiral computed tomography (MSCT) of the lungs.Results ECG data differed on admission and their changes differed for deceased and discharged patients. Of special interest was the effect of the QRS complex duration at baseline and at the end of treatment on the in-hospital survival and mortality rate. The Cox regression analysis showed that the QRS complex duration (relative risk (RR) 2.07, 95% confidence interval (CI): 1.17-3.66; &#x440;=0.01), MSCT data (RR, 1.54; 95&#x200a;% CI: 1.14-2.092; &#x440;=0.005), and glomerular filtration rate (GFR) (RR, 0.98; 95&#x200a;% CI: 0.96-0.99; &#x440;=0.001) had the highest predictive significance. In further comparison of these three indexes, the QRS duration and GFR retained their predictive significance, and a ROC analysis showed that the cut-off QRS complex duration was 125&#x2008;ms (&#x440;=0.001). Patients who developed left bundle branch block (LBBB) in the course of disease also had an unfavorable prognosis compared to other intraventricular conduction disorders (&#x440;=0.038). The presence of LBBB was associated with reduced LV EF (&#x440;=0.0078). The presence of atrial fibrillation (AF) significantly predetermines a worse outcome both at the start (&#x440;=0.011) and at the end of observation (&#x440;=0.034). A higher mortality was observed for the group of deceased patients with ST segment deviations, ST elevation (&#x440;=0.0059) and ST depression (&#x440;=0.028).Conclusion&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Thus, the QTc interval elongation, LBBB that developed during the treatment, AF, and increased QRS complex duration are the indicators that determine the in-hospital prognosis of patients with COVID-19. The strongest electrocardiographic predictor for an unfavorable prognosis was the QRS complex duration that allowed stratification of patients to groups of risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kovtyukh</LastName><ForeName>I V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Petrovsky Russian Scientific Center of Surgery, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baymukanov</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Buyanov Municipal Clinical Hospital, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendlin</LastName><ForeName>G E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>&#x424;&#x413;&#x410;&#x41e;&#x423; &#x412;&#x41e; "&#x420;&#x43e;&#x441;&#x441;&#x438;&#x439;&#x441;&#x43a;&#x438;&#x439; &#x43d;&#x430;&#x446;&#x438;&#x43e;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x44b;&#x439; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x442;&#x435;&#x43b;&#x44c;&#x441;&#x43a;&#x438;&#x439; &#x43c;&#x435;&#x434;&#x438;&#x446;&#x438;&#x43d;&#x441;&#x43a;&#x438;&#x439; &#x443;&#x43d;&#x438;&#x432;&#x435;&#x440;&#x441;&#x438;&#x442;&#x435;&#x442; &#x438;&#x43c;&#x435;&#x43d;&#x438; &#x41d;.&#x418;. &#x41f;&#x438;&#x440;&#x43e;&#x433;&#x43e;&#x432;&#x430;" &#x41c;&#x438;&#x43d;&#x437;&#x434;&#x440;&#x430;&#x432;&#x430; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x438;, &#x41c;&#x43e;&#x441;&#x43a;&#x432;&#x430;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikitin</LastName><ForeName>I G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Pirogov Russian National Research Medical University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dvornikova</LastName><ForeName>S N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Petrovsky Russian Scientific Center of Surgery, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roginko</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Petrovsky Russian Scientific Center of Surgery, Moscow.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Kardiologiia</MedlineTA><NlmUniqueID>0376351</NlmUniqueID><ISSNLinking>0022-9040</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636974</ArticleId><ArticleId IdType="doi">10.18087/cardio.2022.12.n2260</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636973</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0022-9040</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Kardiologiia</Title><ISOAbbreviation>Kardiologiia</ISOAbbreviation></Journal><ArticleTitle>The Effect of COVID-19 on Long-Term Cardiac Function in Patients With Chronic Heart Failure.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>29</EndPage><MedlinePgn>23-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18087/cardio.2022.12.n2265</ELocationID><Abstract><AbstractText>Aim&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; To evaluate functional changes in the heart in the long-term following COVID-19 in patients with chronic heart failure (CHF).Material and methods&#xa0; Case reports of 54 patients aged 69.1&#xb1;9.7 years who had COVID-19 from January 2021 through January 2022 and had been previously diagnosed with NYHA functional class II-III CHF were studied. Two comparison groups were isolated: HF with LV EF &amp;gt;50&#x200a;% (n=39) and &amp;lt;50&#x200a;% (n=15). Echocardiography was used to evaluate changes in LV EF and pulmonary artery systolic pressure (PASP) 5-6 months following COVID-19.Results In all CHF patients after COVID-19 at 5.8 months on average, LV EF decreased (median difference, 2.5&#x200a;%; 95&#x200a;% confidence interval (CI): 6.99&#xd7;10-5-&#x2009;4.99) and PASP increased (median difference, 8&#x2008;mm Hg; 95&#x200a;% CI: 4.5-12.9). In the HF group with LV EF &amp;lt;50&#x200a;%, the decrease in EF was greater than in the group with LV EF &amp;gt;50&#x200a;% (6.9 and 0.7&#x200a;%, respectively; p=0.037); furthermore, the CHF phenotype did not influence the change in PASP (p=0.4). The one-factor regression analysis showed that the dynamics of LV EF decrease was significantly influenced by the baseline decrease in LV EF, whereas the change in PASP was influenced by the dynamics of LV EF decrease, presence of dyslipidemia, and statin treatment. Furthermore, the multifactorial analysis showed that prognostically significant factors for long-term changes in LV EF following COVID-19 were male gender (odds ratio (OR), 5.92; 95&#x200a;% CI: 1.31-26.75; p=0.014), LV EF at baseline &amp;lt;50&#x200a;% (OR, 0.88; 95&#x200a;% CI: 0.8-0.96; p&amp;lt;0.001); changes in PASP depended on the presence of dyslipidemia (OR, 0.08; 95&#x200a;% CI: 0.01-0.84; p=0.018).Conclusion&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; This study showed that COVID-19 in the long term can influence the course of CHF; in this process, HF patients with EF &amp;lt;50&#x200a;% have progression of systolic dysfunction and PASP, whereas patients with EF &amp;gt;50&#x200a;% have an isolated increase in PASP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ageev</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozhevnikova</LastName><ForeName>M V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emelyanov</LastName><ForeName>A V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krivova</LastName><ForeName>A V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shumskaya</LastName><ForeName>Yu F</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Scientific and Practical Clinical Center for Diagnostics and Telemedicine Technologies, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musaeva</LastName><ForeName>L M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popova</LastName><ForeName>L V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naymann</LastName><ForeName>Yu I</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullaeva</LastName><ForeName>G B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Privalova</LastName><ForeName>E V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belenkov</LastName><ForeName>Yu N</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University (Sechenov University), Moscow.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Kardiologiia</MedlineTA><NlmUniqueID>0376351</NlmUniqueID><ISSNLinking>0022-9040</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636973</ArticleId><ArticleId IdType="doi">10.18087/cardio.2022.12.n2265</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636972</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0022-9040</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Kardiologiia</Title><ISOAbbreviation>Kardiologiia</ISOAbbreviation></Journal><ArticleTitle>Proactive anti-inflammatory therapy in the advanced stages of a new coronavirus infection. Main results of the inpatient phase of the COLORIT study (Colchicin vs. Ruxolitinib and secukinumab in an open, prospective, randomized trial in patients with novel coronavirus infection COVID-19).</ArticleTitle><Pagination><StartPage>11</StartPage><EndPage>22</EndPage><MedlinePgn>11-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18087/cardio.2022.12.n2316</ELocationID><Abstract><AbstractText>Aim&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; To evaluate clinical efficacy of the proactive anti-inflammatory therapy in patients hospitalized for COVID-19 with pneumonia and a risk of "cytokine storm".Material and methods&#xa0; The COLORIT study was a comparative study with randomization into 4 groups: colchicine (n=21) 1 mg for the first 3 days followed by 0.5&#x2008;mg/day through day 12 or discharge from the hospital; secukinumab 300&#x2008;mg/day, s.c., as a single dose (n=20); ruxolitinib 5&#x2008;mg, twice a day (n=10); and a control group with no anti-inflammatory therapy (n=22). The effect was evaluated after 12&#xb1;2 days of inpatient treatment or upon discharge, what comes first. For ethical reasons, completely randomized recruitment to the control group was not possible. Thus, for data analysis, 17 patients who did not receive any anti-inflammatory therapy for various reasons not related with inclusion into the study were added to the control group of 5 randomized patients. Inclusion criteria: presence of coronavirus pneumonia (positive PCR test for SARS-CoV-2 RNA or specific clinical presentation of pneumonia; IDC-10 codes U07.1 and U07.2); C-reactive protein (CRP) concentration &amp;gt;60&#x2008;mg/l or its threefold increase from baseline; at least 2 of 4 symptoms (fever &amp;gt;37.5&#x2009;&#xb0;C, persistent cough, shortness of breath with inspiratory rate &amp;gt;20 per min or blood saturation with oxygen &amp;lt;94&#x200a;% by the 7th-9th day of disease. The study primary endpoint was changes in COVID Clinical Condition Scale (CCS-COVID) score. The secondary endpoints were the dynamics of CRP and changes in the area of lung lesion according to data of computed tomography (CT) of the lungs from the date of randomization to 12&#xb1;2 days.Results All three drugs significantly reduced inflammation, improved the clinical course of the disease, and decreased the disease severity as evaluated by the CCS score: in the ruxolitinib group, by 5.5 (p=0.004); in the secukinumab group, by 4 (p=0.096); in the colchicine group, by 4 (p=0.017), and in the control group, by 2 (&#x440;=0.329). In all three groups, the CCS-COVID score was 2-3 by the end of observation period, which corresponded to a mild process, while in the control group, the score was 7 (&#x440;=0.005). Time-related changes in CRP were significant in all three anti-inflammatory treatment groups with no statistical difference between the groups. By the end of the study, changes in CT of the lungs were nonsignificant.Conclusion&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; In severe &#x421;OVID-19 with a risk of "cytokine storm", the proactive therapy with ruxolitinib, colchicine, and secukinumab significantly reduces the inflammation severity, prevents the disease progression, and results in clinical improvement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mareev</LastName><ForeName>V Yu</ForeName><Initials>VY</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orlova</LastName><ForeName>Y&#x430; A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plisuk</LastName><ForeName>A G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlikova</LastName><ForeName>E P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akopyan</LastName><ForeName>Z A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matskeplishvili</LastName><ForeName>S T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malahov</LastName><ForeName>P S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krasnova</LastName><ForeName>T N</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seredenina</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potapenko</LastName><ForeName>A V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agapov</LastName><ForeName>&#x41c; A</ForeName><Initials>&#x41c;A</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asratyan</LastName><ForeName>D A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dyachuk</LastName><ForeName>L I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samokhodskaya</LastName><ForeName>L M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mershina</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinitsyn</LastName><ForeName>V E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mareev</LastName><ForeName>Yu V</ForeName><Initials>YV</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; National Medical Research Center of Therapy and Preventive Medicine, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shatokhina</LastName><ForeName>E A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Begrambekova</LastName><ForeName>Yu L</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamalov</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Medical Research and Educational Center, Lomonosov Moscow State University, Moscow; School of Fundamental Medicine, Lomonosov Moscow State University, Moscow.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Kardiologiia</MedlineTA><NlmUniqueID>0376351</NlmUniqueID><ISSNLinking>0022-9040</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636972</ArticleId><ArticleId IdType="doi">10.18087/cardio.2022.12.n2316</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636959</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-0496</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Pediatric pulmonology</Title><ISOAbbreviation>Pediatr Pulmonol</ISOAbbreviation></Journal><ArticleTitle>How has the SARS-CoV-2 pandemic changed the epidemiology and management of acute bronchiolitis?</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ppul.26315</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">SARS-COV-2 pandemic profoundly impacted acute bronchiolitis epidemiology worldwide, especially RSV diffusion and burden of disease, with remarkable implications on the management of health resources. We aimed to study the epidemiology and clinical course of bronchiolitis in the past five years in our region and to assess the trends that occurred during and after the SARS-COV-2 pandemic METHODS: We conducted an observational study including all children aged 0-2 years with bronchiolitis admitted to a tertiary children's hospital during the last 5 years. Demographic, clinical, and microbiological data were collected. Comparisons between patient subgroups were carried out.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 647 patients admitted for bronchiolitis were included (median age 78 days). Molecular diagnostic tests were performed in 617 patients (95.4%) with RSV detected in 51.5% of patients in pre-pandemic years and 74.5% in pandemic years. Through the study period, we observed a progressive increase in the number of children requiring respiratory support, RSV infections, and children with a history of prematurity. Conversely, this was not true for mechanical ventilation, duration of respiratory support, ICU admission, and length of stay.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical course and epidemiology of bronchiolitis showed a significant change through the study years with a heavy impact during the 2021-22 season. The increase in the number of patients requiring respiratory support, although not associated with an increase in mechanical ventilation, may be explained by the higher prevalence of RSV. The change in epidemiology highlights the importance of surveillance systems to monitor RSV circulation, in order to plan prophylactic strategies, and prepare healthcare systems. This article is protected by copyright. All rights reserved.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brisca</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7992-0181</Identifier><AffiliationInfo><Affiliation>Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2989-7301</Identifier><AffiliationInfo><Affiliation>Unit&#xe0; di Malattie Infettive e COVID Hospital, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit&#xe0; degli Studi di Genova, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buratti</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Terapia Intensiva Neonatale e Pediatrica, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferretti</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatria d'Urgenza e Pronto Soccorso, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirlo</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buffoni</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallamaci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvati</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit&#xe0; di Pneumologia Pediatrica e Endoscopia Respiratoria, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagliarini</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit&#xe0; degli Studi di Genova, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccotti</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pediatria d'Urgenza e Pronto Soccorso, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Oliviero</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-9350-9134</Identifier><AffiliationInfo><Affiliation>Unit&#xe0; di Pneumologia Pediatrica e Endoscopia Respiratoria, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castagnola</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unit&#xe0; di Malattie Infettive e COVID Hospital, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moscatelli</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Terapia Semintensiva, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Terapia Intensiva Neonatale e Pediatrica, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Pulmonol</MedlineTA><NlmUniqueID>8510590</NlmUniqueID><ISSNLinking>1099-0496</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 pandemic</Keyword><Keyword MajorTopicYN="N">bronchiolitis</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">palivizumab</Keyword><Keyword MajorTopicYN="N">respiratory syncytial virus (RSV)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636959</ArticleId><ArticleId IdType="doi">10.1002/ppul.26315</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636955</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ciad016</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciad016</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2 vaccination in solid organ transplant (SOT) is associated with poorer antibody response (AbR) compared to non-SOT recipients. However, its impact on the risk of breakthrough infection (BI) should yet be assessed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Single-center prospective longitudinal cohort study enrolling adult SOT recipients who received SARS-CoV2 vaccination during 1-year period from February 2021, and followed-up to April 30th 2022. Patients were tested for AbR at multiple timepoints. Primary endpoint was BI (laboratory confirmed SARS-CoV2 infection &#x2265;14 days after 2nd dose). Immunization (positive AbR) was considered an intermediate state between vaccination and BI. Probabilities of being in vaccination, immunization and BI states were obtained for each type of graft and vaccination sequence with multistate survival analysis, then multivariable logistic regression was performed to analyse the risk of BI in AbR levels.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">614 SOT (275 kidney, 163 liver, 137 heart, 39 lung) recipients were included. Most patients (84.7%) received three vaccine doses, the first two consisted of BNT162b2 and mRNA-1273 in 73.5% and 26.5% of cases, respectively; while at the third dose mRNA-1273 was administered in 59.8% of patients. Overall, 75.4% of patients reached immunization and 18.4% developed BI. Heart transplant recipients showed lowest probability of immunization (0.418) and highest of BI (0.323), all-mRNA-1273 vaccine-sequence showed higher probability of immunization (0.732) and lowest of BI (0.098). Risk of BI was higher for non-high-level AbR, younger age and shorter time from transplant.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SOT patients with non-high-level AbR, shorter time from transplantation, and heart recipients are at highest risk of BI.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonazzetti</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tazza</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibertoni</LastName><ForeName>Dino</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Research and Innovation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquini</LastName><ForeName>Zeno</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caroccia</LastName><ForeName>Natascia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan&#xec;</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornaro</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascale</LastName><ForeName>Renato</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miani</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamberini</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Maria Cristina</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Internal Medicine Unit for the treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam&#xe9;</LastName><ForeName>Mariarosa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busutti</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nephrology, Dialysis and Transplantation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comai</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Nephrology, Dialysis and Transplantation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potena</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit of Heart Failure and Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borgese</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit of Heart Failure and Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvaterra</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Interventional Pulmonology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazzarotto</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scudeller</LastName><ForeName>Luigia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research and Innovation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viale</LastName><ForeName>Pierluigi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannella</LastName><ForeName>Maddalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna &#xa0;Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CONTRAST study group
</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV2 infection</Keyword><Keyword MajorTopicYN="N">antibody-response</Keyword><Keyword MajorTopicYN="N">mRNA vaccines</Keyword><Keyword MajorTopicYN="N">multistate model</Keyword><Keyword MajorTopicYN="N">serology</Keyword><Keyword MajorTopicYN="N">solid organ transplantation</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Di Chiara</LastName><ForeName>Michela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giacomini</LastName><ForeName>Maria Eugenia</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vatamanu</LastName><ForeName>Oana</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horna</LastName><ForeName>Clara Solera</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campoli</LastName><ForeName>Caterina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartoletti</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bussini</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trapani</LastName><ForeName>Fabio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Attard</LastName><ForeName>Luciano</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gatti</LastName><ForeName>Milo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gramegna</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>La Manna</LastName><ForeName>Gaetano</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grandinetti</LastName><ForeName>Valeria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demetri</LastName><ForeName>Marcello</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbuto</LastName><ForeName>Simona</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abenavoli</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vitale</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turco</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravaioli</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cescon</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertuzzo</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messina</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trombi</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masetti</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prestinenzi</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabatino</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giovannini</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alessio</LastName><ForeName>Aloisio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scuppa</LastName><ForeName>Maria Francesca</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolci</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paganelli</LastName><ForeName>Gianmaria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabrielli</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pavoni</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leone</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lanna</LastName><ForeName>Federica</ForeName><Initials>F</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636955</ArticleId><ArticleId IdType="doi">10.1093/cid/ciad016</ArticleId><ArticleId IdType="pii">6986430</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636919</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4571</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Circulation research</Title><ISOAbbreviation>Circ Res</ISOAbbreviation></Journal><ArticleTitle>Toll-Like Receptor 4-Dependent Platelet-Related Thrombosis in SARS-CoV-2 Infection.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCRESAHA.122.321541</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2 is associated with an increased risk of venous and arterial thrombosis, but the underlying mechanism is still unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a cross-sectional analysis of platelet function in 25 SARS-CoV-2 and 10 healthy subjects by measuring Nox2 (NADPH oxidase 2)-derived oxidative stress and thromboxane B<sub>2</sub>, and investigated if administration of monoclonal antibodies against the S protein (Spike protein) of SARS-CoV-2 affects platelet activation. Furthermore, we investigated in vitro if the S protein of SARS-CoV-2 or plasma from SARS-CoV-2 enhanced platelet activation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ex vivo studies showed enhanced platelet Nox2-derived oxidative stress and thromboxane B<sub>2</sub> biosynthesis and under laminar flow platelet-dependent thrombus growth in SARS-CoV-2 compared with controls; both effects were lowered by Nox2 and TLR4 (Toll-like receptor 4) inhibitors. Two hours after administration of monoclonal antibodies, a significant inhibition of platelet activation was observed in patients with SARS-CoV-2 compared with untreated ones. In vitro study showed that S protein per se did not elicit platelet activation but amplified the platelet response to subthreshold concentrations of agonists and functionally interacted with platelet TLR4. A docking simulation analysis suggested that TLR4 binds to S protein via three receptor-binding domains; furthermore, immunoprecipitation and immunofluorescence showed S protein-TLR4 colocalization in platelets from SARS-CoV-2. Plasma from patients with SARS-CoV-2 enhanced platelet activation and Nox2-related oxidative stress, an effect blunted by TNF (tumor necrosis factor) &#x3b1; inhibitor; this effect was recapitulated by an in vitro study documenting that TNF&#x3b1; alone promoted platelet activation and amplified the platelet response to S protein via p47phox upregulation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study identifies 2 TLR4-dependent and independent pathways promoting platelet-dependent thrombus growth and suggests inhibition of TLR4. or p47phox as a tool to counteract thrombosis in SARS-CoV-2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Carnevale</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6216-9595</Identifier><AffiliationInfo><Affiliation>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (R.C., S.S., G.F., M.L.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Neuromed, Localit&#xe0; Camerelle, Pozzilli (IS), Italy (R.C., S.S., G.F.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cammisotto</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., S.B., C.N., L.L., P.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartimoccia</LastName><ForeName>Simona</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6266-3059</Identifier><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., S.B., C.N., L.L., P.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nocella</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., S.B., C.N., L.L., P.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellani</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of General Surgery and Surgical Speciality, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., F.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bufano</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6359-5978</Identifier><AffiliationInfo><Affiliation>Laboratory affiliated with the Institute Pasteur Italy - Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Italy. (M.B., A.C., R.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loffredo</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6542-6235</Identifier><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., S.B., C.N., L.L., P.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sciarretta</LastName><ForeName>Sebastiano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8633-6896</Identifier><AffiliationInfo><Affiliation>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (R.C., S.S., G.F., M.L.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Neuromed, Localit&#xe0; Camerelle, Pozzilli (IS), Italy (R.C., S.S., G.F.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frati</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2703-3761</Identifier><AffiliationInfo><Affiliation>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (R.C., S.S., G.F., M.L.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Neuromed, Localit&#xe0; Camerelle, Pozzilli (IS), Italy (R.C., S.S., G.F.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coluccia</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory affiliated with the Institute Pasteur Italy - Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Italy. (M.B., A.C., R.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silvestri</LastName><ForeName>Romano</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory affiliated with the Institute Pasteur Italy - Cenci Bolognetti Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Italy. (M.B., A.C., R.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceccarelli</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5921-3180</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico, Italy. (G.C., A.O., M.V., C.M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliva</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0832-7975</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico, Italy. (G.C., A.O., M.V., C.M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venditti</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico, Italy. (G.C., A.O., M.V., C.M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugliese</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of General Surgery and Surgical Speciality, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., F.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maria Mastroianni</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico, Italy. (G.C., A.O., M.V., C.M.M.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turriziani</LastName><ForeName>Ombretta</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6400-9168</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, Viale del Policlinico, Italy. (O.T.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leopizzi</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9258-4191</Identifier><AffiliationInfo><Affiliation>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (R.C., S.S., G.F., M.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Amati</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Italy. (G.D.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pignatelli</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2265-7455</Identifier><AffiliationInfo><Affiliation>Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, Italy. (V.C., S.B., C.N., L.L., P.P.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mediterranea Cardiocentro-Napoli, Italy (P.P., F.V.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Violi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6610-7068</Identifier><AffiliationInfo><Affiliation>Mediterranea Cardiocentro-Napoli, Italy (P.P., F.V.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circ Res</MedlineTA><NlmUniqueID>0047103</NlmUniqueID><ISSNLinking>0009-7330</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword><Keyword MajorTopicYN="N">thromboxane B2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636919</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.122.321541</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636865</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-6518</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of interpersonal violence</Title><ISOAbbreviation>J Interpers Violence</ISOAbbreviation></Journal><ArticleTitle>The Effect of the Covid-19 Pandemic on Domestic Violence in Germany: A Comparison of Three Representative Population Surveys.</ArticleTitle><Pagination><StartPage>8862605221143194</StartPage><MedlinePgn>8862605221143194</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/08862605221143194</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has had profound societal and economic effects. Concerns were raised that domestic violence might increase because of the enacted infection control measures. Previous findings on this issue have been contradictory. Since existing studies mainly rely on official reports, administrative data, helpline calls, or retrospective measures, their findings are likely to prove unreliable. Few population-based surveys include pre-pandemic data, limiting their ability to test for causality regarding increasing violence. Therefore, the aim of this study was to compare findings from population-representative surveys on the prevalence of intimate partner violence (IPV) and violence against children (VAC) before and during the COVID-19 pandemic. Based on the data of <i>N</i>&#x2009;=&#x2009;3,639 individuals living with a romantic partner and <i>N</i>&#x2009;=&#x2009;1,313 parents living with at least one of their children from three German representative population surveys, we estimated average marginal effects for the temporal trends (i.e., pre vs. post infection control measures) of domestic violence separately for males and females. To minimize bias across survey waves, inverse probability weighting was used. Results show no statistically significant increase in either physical or psychological forms of IPV or VAC as a result of the implementation of COVID measures. On the contrary, the 1-year prevalence was decreasing for certain forms of violence. Our findings suggest that the assessment of the consequences of infection control measures needs an empirical basis. Further research should be conducted using high-quality data sources. Therefore, the present study should be considered a stepping stone for ongoing research efforts to examine the consequences of pandemic-related infection control measures on the general population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kliem</LastName><ForeName>S&#xf6;ren</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1788-9574</Identifier><AffiliationInfo><Affiliation>University of Applied Science, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Thadden</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6219-8495</Identifier><AffiliationInfo><Affiliation>University of Hildesheim, Hildesheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohmann</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Applied Science, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xf6;ger</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Hildesheim, Hildesheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baier</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ZHAW Zurich University of Applied Sciences, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Interpers Violence</MedlineTA><NlmUniqueID>8700910</NlmUniqueID><ISSNLinking>0886-2605</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">assessment</Keyword><Keyword MajorTopicYN="N">child abuse</Keyword><Keyword MajorTopicYN="N">domestic violence</Keyword><Keyword MajorTopicYN="N">mental health and violence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636865</ArticleId><ArticleId IdType="doi">10.1177/08862605221143194</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636856</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1541-3764</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Omega</Title><ISOAbbreviation>Omega (Westport)</ISOAbbreviation></Journal><ArticleTitle>Bereaved in Me: Understanding the Vicarious Grief Experiences Among Helping Professionals During the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>302228221150870</StartPage><MedlinePgn>302228221150870</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/00302228221150870</ELocationID><Abstract><AbstractText>Literature on the experience of the bereaved during the COVID-19 pandemic suggests how complicated it has been for those who lost loved ones. However, the sense of grief experienced by those who journey with them is relatively unexplored. The present study examines vicarious experiences of grief of healthcare workers, faith-based workers and mental health workers who worked with the bereaved due to COVID-19 deaths. The study was done in two phases. In the first phase, a survey showed that compared to other helping professionals, healthcare workers reported the highest levels of vicarious grief. In the second phase, in-depth interviews revealed five themes: acknowledging contexts of grief, navigating relations with the bereaved, sharing others' grief, internalizing encounters, and negotiating challenges. Findings highlight the need for supportive interventions at the organizational level.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sera Jose</LastName><ForeName>Kaina Marie Clare</ForeName><Initials>KMC</Initials><AffiliationInfo><Affiliation>Department of Psychology, 595658Ateneo de Manila University, Quezon City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Agham Josiah</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Psychology, 595658Ateneo de Manila University, Quezon City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomida</LastName><ForeName>Angelo Nico</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0001-6959-1791</Identifier><AffiliationInfo><Affiliation>Department of Psychology, 595658Ateneo de Manila University, Quezon City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hechanova-Alampay</LastName><ForeName>Maria Regina</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Psychology, 595658Ateneo de Manila University, Quezon City, Philippines.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Omega (Westport)</MedlineTA><NlmUniqueID>1272106</NlmUniqueID><ISSNLinking>0030-2228</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">coping</Keyword><Keyword MajorTopicYN="N">helping professionals</Keyword><Keyword MajorTopicYN="N">mixed methods</Keyword><Keyword MajorTopicYN="N">vicarious grief</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636856</ArticleId><ArticleId IdType="doi">10.1177/00302228221150870</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636854</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0374-9096</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Mikrobiyoloji bulteni</Title><ISOAbbreviation>Mikrobiyol Bul</ISOAbbreviation></Journal><ArticleTitle>[How to Defend Mandatory Immunization Against Vaccine Hesitancy and Vaccine Refusal? An Ethical Assessment].</ArticleTitle><Pagination><StartPage>156</StartPage><EndPage>170</EndPage><MedlinePgn>156-170</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5578/mb.20239913</ELocationID><Abstract><AbstractText>One of the basic ethical principles in medical practice is to respect personal autonomy. However, it is a widely accepted view that when it comes to health problems that concern not only the individual but also the society, especially in epidemics of infectious diseases, individual autonomy can be violated by prioritizing the benefit of the community. This view is based on the scientific fact that epidemics can only be controlled by immunizing all susceptible individuals. However, whether all susceptible individuals can be compelled to be immunized remains a matter of debate around the world. Especially in the last three years, during the worldwide Coronavirus disease-2019 (COVID-19) pandemic, a significant part of the society has been hesitant about being vaccinated, and some have argued that vaccines should be rejected altogether. In the face of the situation outlined above, the question of "should immunization be mandatory?" has become more important than ever to be able to answer the question in a way that will ensure as broad consensus as possible. In this review article; it was discussed under which conditions mandatory immunization could be justified in terms of ethics and thus, it was aimed to contribute to the solution of the vital problem created by the phenomenon of vaccine hesitancy and rejection in terms of public health. To this aim, first of all, the need to clarify some concepts was mentioned. Afterwards, the arguments "must be compulsory", "should be optional", and "should not be done to anyone" were evaluated with their justifications and it was determined that the argument that immunization should be mandatory could be justified in terms of ethics. In the article, it was argued that the conflicts of "individual freedom X community benefit" and "personal autonomy X community benefit" did not exist in today's actual conditions, but it was stated that an individual with the knowledge of reality experiences a tension in the face of not putting this knowledge into practice. It was emphasized that in order to overcome this tension, consolidation of the theoretical background and also consideration of the macro determinants of vaccine hesitancy and rejection in practice were necessary. What needs to be done to re-establish trust in the medical institution was listed, and it was argued that the question of how to implement mandatory immunization could only be answered in a healthy way through a transformation process that will be implemented through a social dialogue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Civaner</LastName><ForeName>M Murat</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Bursa Uluda&#x11f; University Faculty of Medicine, Department of Medical History and Ethics, Bursa, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>A&#x15f;&#x131; Karars&#x131;zl&#x131;&#x11f;&#x131; ve A&#x15f;&#x131; Reddi Olgusu Kar&#x15f;&#x131;s&#x131;nda Zorunlu Ba&#x11f;&#x131;&#x15f;&#x131;klama Nas&#x131;l Savunulmal&#x131;? Etik A&#xe7;&#x131;s&#x131;ndan Bir De&#x11f;erlendirme.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Mikrobiyol Bul</MedlineTA><NlmUniqueID>7503830</NlmUniqueID><ISSNLinking>0374-9096</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636854</ArticleId><ArticleId IdType="doi">10.5578/mb.20239913</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636849</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0374-9096</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Mikrobiyoloji bulteni</Title><ISOAbbreviation>Mikrobiyol Bul</ISOAbbreviation></Journal><ArticleTitle>[Evaluation of the Effects of Tocilizumab Use on Oxygen Parameters, Inflammatory Markers and Survival in Patients Diagnosed with COVID-19 in Intensive Care Unit].</ArticleTitle><Pagination><StartPage>97</StartPage><EndPage>107</EndPage><MedlinePgn>97-107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5578/mb.20239908</ELocationID><Abstract><AbstractText>Inflammation plays a key role in the progression of COVID-19 infection from acute viral disease to organ failure and death. Tocilizumab maintains its current place as a frequently preferred agent in hyperinflammatory syndrome in COVID-19 infection. This study was aimed to evaluate changes in oxygen parameters and inflammatory markers before and after treatment, to define survival rates and complications in the patients who have been followed up in the tertiary intensive care unit of our hospital with the diagnosis of COVID-19 and who have been administered tocilizumab for hyperinflammatory syndrome in the follow-up. This study was planned as a retrospective observational study. A total of 132 patients were included in the study. The patient's data; age, comorbidities, sequential organ failure assessment (SOFA) and acute physiologic assessment and chronic health evaluation II (APACHE II) scores, duration of stay on a mechanical ventilator, duration of stay in the intensive care unit, positivity of real-time polymerase chain reaction (Rt-PCR), the presence of lung tomography findings specific to SARS-CoV-2 pneumonia, survival data, laboratory parameters, lactate mmol/L, partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PCO2), oxygen saturation % (SpO2) and partial pressure of oxygen/inspired oxygen (PaO2/FiO2) values on hospitalization date, tocilizumab administration date and post-administration days one, three, five, and seven; treatments administered and drug complications were recorded. IBM SPSS Version 25.0 statistical package program was used for statistical analysis. Of the 132 patients, 36 were female and 96 were male (p= 0.972). The mean age was 61.9 &#xb1; 1.07 years, the mean APACHE 2 score &#xb1; standard deviation (SD) was 14.89 &#xb1; 5.22 and mortality was 41.7%. The mean duration on a mechanical ventilator was 9.54 &#xb1; 15.63 days and the mean length of stay in the intensive care unit was 20.50 &#xb1; 15.48 days. A statistically significant difference was found between the PaO2, SpO2, and the PaO2/FiO2 values on the day of hospitalization and days one, three, five, and seven after tocilizumab administration, and also between the day of tocilizumab administration and days following the administration (p&lt;0.001). There was a significant decrease in ferritin, D-dimer, and C-reactive protein levels, and a significant increase in the lymphocyte count (p&lt;0.05). Elevated transaminases (n= 36), acute renal injury (n= 25), atrial fibrillation (n= 10), pneumothorax (n= 10), and pneumomediastinum (n= 6) were the most common complications during the disease. In our study, a significant improvement was observed in inflammatory parameters and oxygen parameters from the first day after tocilizumab administration. In the first seven days patient mortality was zero with improvement in the P/F ratios. These data supported the opinion that tocilizumab might be an effective treatment option for COVID-19 infection. In addition to the potential benefits of tocilizumab in critical COVID-19 patients, it is essential that the side effects related to the use of the drug be closely monitored, and early identification of and intervention in thromboembolic events increases survival.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Y&#x131;lmaz</LastName><ForeName>Berna</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Manisa City Hospital, Clinic of Anesthesiology Reanimation and Intensive Care, Manisa, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do&#x11f;an</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tekirda&#x11f; &#xc7;orlu State Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Tekirda&#x11f;, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ergut Sezer</LastName><ForeName>B&#xfc;&#x15f;ra</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tekirda&#x11f; &#xc7;orlu State Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Tekirda&#x11f;, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Yo&#x11f;un Bak&#x131;mda COVID-19 Tan&#x131;l&#x131; Hastalarda Tosilizumab Kullan&#x131;m&#x131;n&#x131;n Oksijen Parametreleri, Enflamatuvar Belirte&#xe7;ler ve Sa&#x11f;kal&#x131;m &#xdc;zerine Etkilerinin De&#x11f;erlendirilmesi.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Mikrobiyol Bul</MedlineTA><NlmUniqueID>7503830</NlmUniqueID><ISSNLinking>0374-9096</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636849</ArticleId><ArticleId IdType="doi">10.5578/mb.20239908</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">36636846</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0374-9096</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Mikrobiyoloji bulteni</Title><ISOAbbreviation>Mikrobiyol Bul</ISOAbbreviation></Journal><ArticleTitle>[Long COVID in Children: A Pediatric Center Experience].</ArticleTitle><Pagination><StartPage>60</StartPage><EndPage>70</EndPage><MedlinePgn>60-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5578/mb.20239905</ELocationID><Abstract><AbstractText>Although COVID-19 (Coronavirus disease-2019) is observed to be milder in children, it has been observed that the symptoms continue for a long time in many people after the acute period of the disease, especially the multisystemic inflammatory syndrome (MISC) that developed after COVID-19 with the progression of the pandemic. Although it was first defined by different names such as long COVID and post COVID in adults, it has been observed in studies that similar complaints such as cough, fatigue and difficulty in concentrating continue for a long time in children, just as in adults. In our study, we aimed to evaluate the status of long COVID in childhood. Our study included patients aged from one month to 18 years with moderate and severe symptoms who were hospitalized and discharged for SARS-CoV-2 infection in &#x130;stanbul University Faculty of Medicine between November 1, 2020 and November 1, 2021. A questionnaire form was created to learn about the complaints of the patients and their ongoing complaints. The patients/parents were called by phone and their complaints were recorded in the questionnaire. The patients were classified according to the definitions in the guidelines published by NICE, RCGP and SIGN. In total, 116 patients were included; 57.8% (n= 64) male, 42.5% (n= 49) female; 53.4% (n= 62) 0-9, 46.6% (n= 54) 10-18 years old. Comorbid conditions were found in 64 (55.2%) patients. The mean follow-up period was 5.90 &#xb1; 3.61 [min-max (1-12)] months; longest symptom durations: decrease in effort loss/fatigue 19.25 &#xb1; 74.56 (0-365) days, concentration difficulties 11.12 &#xb1; 49.75 (0-365) days, fatigue 9.61 &#xb1; 34.96 (0-365) days and cough were 8.34 &#xb1; 35.37 (0-365) days. The percentage of the patients who met the definition of subacute/ongoing symptomatic COVID-19 was 37.9% (n= 44). The most common symptoms were the decrease of effort capacity/fatigue 12.1% (n= 14) and the concentration difficulties 10.3% (n= 12) in subacute symptomatic patients. The percentage of patients matching the definition of chronic/post COVID-19 was 11.2% (n= 13). In the first year of the disease, ongoing complaints such as fatigue and concentration difficulties were observed in eight patients. The rate of concentration difficulties in the 10-18 age group was statistically significantly higher than the 0-9 age group (p= 0.037). In terms of other symptoms, no significant difference was found according to age, gender and concomitant disease status. Out of these, one patient was diagnosed with Type 2 diabetes mellitus during the acute illness, and two patients were diagnosed with allergic rhinitis after COVID-19. A statistically significant difference was found in the rates of concentration disorders according to age groups with subacute/ongoing symptoms. Although only the hospitalized patients were included, fatigue and difficulty in concentration were among the most common ongoing symptoms in our study, similar to the literature, and they were seen to be more common in older children. It is important both for early diagnosis and awareness to follow up children with COVID-19 in terms of symptoms, not only in terms of prolonged symptoms but also in terms of new diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Demirbu&#x11f;a</LastName><ForeName>Asuman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han&#xe7;erli T&#xf6;r&#xfc;n</LastName><ForeName>Selda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaba</LastName><ForeName>&#xd6;zge</ForeName><Initials>&#xd6;</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dede</LastName><ForeName>Elif</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mete Atasever</LastName><ForeName>Neslihan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ery&#x131;lmaz</LastName><ForeName>Cansu Ceren</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okay</LastName><ForeName>Necla Simay</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somer</LastName><ForeName>Ayper</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>&#x130;stanbul University Faculty of Medicine, Department of Child Health and Diseases, Division of Pediatric Infectious Diseases, &#x130;stanbul, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>COVID-19 Nedeniyle Hastanede Yatan &#xc7;ocuk Hastalarda Uzun D&#xf6;nem Etkilerin ve Uzam&#x131;&#x15f; COVID S&#x131;kl&#x131;&#x11f;&#x131;n&#x131;n De&#x11f;erlendirilmesi.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Mikrobiyol Bul</MedlineTA><NlmUniqueID>7503830</NlmUniqueID><ISSNLinking>0374-9096</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636846</ArticleId><ArticleId IdType="doi">10.5578/mb.20239905</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636830</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0301-1526</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>VASA. Zeitschrift fur Gefasskrankheiten</Title><ISOAbbreviation>Vasa</ISOAbbreviation></Journal><ArticleTitle>Spontaneous dissection of the superior mesenteric artery related to COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1024/0301-1526/a001051</ELocationID><Abstract><AbstractText><b/><i>Background:</i> Spontaneous peripheral dissections are rare, and in a substantial number of cases, the underlying aetiology remains unclear. <i>Patients and methods:</i> We report the case of a 63-year-old male patient with a recent asymptomatic SARS-CoV-2 infection who presented with sudden-onset intermittent abdominal pain. Imaging studies revealed a dissection of the superior mesenteric artery (SMA) and large-vessel vasculitis involving the SMA as well as the carotid, subclavian, axillary and femoropopliteal arteries. In the absence of other predisposing factors, we supposed an association with prior COVID-19 and performed a systematic review of the literature to search for similar cases with arterial dissection related to acute or recent SARS-CoV-2 infection. <i>Results:</i> We identified 25 cases, including ours: 13 males and 12 females, with a median age of 48 years. In 22/25 patients, arterial dissection occurred within 4 weeks after the diagnosis of COVID-19 and involved the cerebral (11/25; 44%), coronary (10/25; 40%), splanchnic (3/25; 12%) and renal (2/25; 8%) arteries. <i>Conclusions:</i> Although initially known for its respiratory manifestations, it has become evident that SARS-CoV-2 not only infects pneumocytes but also enters the vascular endothelium, leading to endothelial dysfunction and hypercoagulability and - as shown in our case - large-vessel vasculitis, which may predispose patients to intramural haemorrhage and arterial dissection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kukulski</LastName><ForeName>Leszek</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0906-9509</Identifier><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac, Vascular and Endovascular Surgery and Tranplantology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scharf</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiology, Interventional Radiology, University Hospital Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schierling</LastName><ForeName>Wilma</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfister</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linnemann</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Angiology, East Bavarian Center of Vascular Medicine, University Hospital Regensburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vasa</MedlineTA><NlmUniqueID>0317051</NlmUniqueID><ISSNLinking>0301-1526</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">arterial dissection</Keyword><Keyword MajorTopicYN="N">superior mesenteric artery</Keyword><Keyword MajorTopicYN="N">vasculitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636830</ArticleId><ArticleId IdType="doi">10.1024/0301-1526/a001051</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636828</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-0254</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of biomolecular structure &amp; dynamics</Title><ISOAbbreviation>J Biomol Struct Dyn</ISOAbbreviation></Journal><ArticleTitle>Investigation of the interactions of HSA and SARS-CoV-2 papain-like protease against eugenol for novel COVID-19 drug discovery: spectroscopic and insilico study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>10</EndPage><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/07391102.2022.2164062</ELocationID><Abstract><AbstractText>Coronavirus family consist of a member known as SARS-CoV-2, spread drastically in 2019 (Covid-19), affecting millions of people worldwide. Till date there is no clear-clinical therapy or drug, targeted to cure this serious disease. Researches are going on to prevent this corona virus. Here, we tried to explore a novel SARS-CoV-2 papain-like protease as a potential inhibitor. Finally, eugenol was docked with this protease to find prime SARS-inhibitors. <i>In silico</i> studies revealed that eugenol binds to the active site of SARS-CoV-2 papain-like protease with appropriate binding. Moreover, the MD simulation for 100&#x2009;ns and MMPBSA calculation reveals that eugenol possess potential phytotherapeutic properties against COVID-19. The interaction of eugenol with human serum albumin has been examined by using fluorescence, UV-vis spectroscopy, circular dichroism as well as computational techniques such as molecular docking, molecular dynamic simulation and MMPBSA calculation. Overall investigation shows eugenol having good affinity for HSA <i>K</i><sub>a</sub> 6.80&#x2009;&#xd7;&#x2009;10<sup>6</sup> M<sup>-1</sup>.Communicated by Ramaswamy H. Sarma.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naz</LastName><ForeName>Farheen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biosciences, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Imran</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Deanship of Educational Services, Qassim University, Buraidah, Al Qassim, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baammi</LastName><ForeName>Soukayna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>African Genome Centre (AGC), Mohammed VI Polytechnic University, Benguerir, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Asimul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomol Struct Dyn</MedlineTA><NlmUniqueID>8404176</NlmUniqueID><ISSNLinking>0739-1102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">HSA</Keyword><Keyword MajorTopicYN="N">MD simulation</Keyword><Keyword MajorTopicYN="N">MMPBSA calculation</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">eugenol</Keyword><Keyword MajorTopicYN="N">fluorescence</Keyword><Keyword MajorTopicYN="N">protease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636828</ArticleId><ArticleId IdType="doi">10.1080/07391102.2022.2164062</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636825</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1346-8138</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of dermatology</Title><ISOAbbreviation>J Dermatol</ISOAbbreviation></Journal><ArticleTitle>Cutaneous manifestations of COVID-19 and COVID-19 vaccination.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/1346-8138.16651</ELocationID><Abstract><AbstractText>In December 2019, a new infectious pathogen named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China. Transmitted through respiratory droplets, SARS-CoV-2 is the causative pathogen of coronavirus disease 2019 (COVID-19). Although this new COVID-19 infection is known to cause primarily interstitial pneumonia and respiratory failure, it is often associated with cutaneous manifestations as well. These manifestations with COVID-19 can be classified into seven categories: (i) chilblain-like skin eruption (e.g., COVID toes), (ii) urticaria-like skin eruption, (iii) maculopapular lesions, (iv) vesicular eruptions, (v) purpura, (vi) livedo reticularis and necrotic lesions, (vii) urticarial vasculitis, and others such as alopecia and herpes zoster. The pathogenesis of skin eruptions can be broadly divided into vasculitic and inflammatory skin eruptions. Various cutaneous adverse reactions have also been observed after COVID-19 mRNA vaccination. The major cutaneous adverse reactions are type I hypersensitivity (urticaria and anaphylaxis) and type IV hypersensitivity (COVID arm and erythema multiform). Autoimmune-mediated reactions including bullous pemphigus, vasculitis, vitiligo, and alopecia areata have also been reported. Several cases with chilblain-like lesions and herpes zoster after COVID-19 mRNA vaccination have been published. Various skin diseases associated with COVID-19 and COVID-19 vaccination have been reported, and the mechanism has been partly elucidated. In the process, for example, some papers have reported that it is not related to COVID-19 infection, although it was initially called COVID-toe and considered a COVID-19-associated cutaneous eruption. In fact, some COVID-19-associated skin reactions are indistinguishable from drug eruptions. In the future, the mechanisms of COVID-19- or COVID-19 vaccine-associated skin reactions need to be elucidated and verification of causal relationships is required.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. The Journal of Dermatology published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Dermatological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakashima</LastName><ForeName>Chisa</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9653-6824</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, Kindai University Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Maiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, Kindai University Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, Kindai University Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Dermatol</MedlineTA><NlmUniqueID>7600545</NlmUniqueID><ISSNLinking>0385-2407</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636825</ArticleId><ArticleId IdType="doi">10.1111/1346-8138.16651</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-42.</Citation></Reference><Reference><Citation>McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85:46-55.</Citation></Reference><Reference><Citation>Zhao Q, Fang X, Pang Z, Zhang B, Liu H, Zhang F. COVID-19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatology Venereol. 2020;34:2505-10.</Citation></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-80.e8.</Citation></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, M&#xf8;ller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036-45.e9.</Citation></Reference><Reference><Citation>Magro C, Nuovo G, Mulvey JJ, Laurence J, Harp J, Crowson AN. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clin Dermatol. 2021;39:934-65.</Citation></Reference><Reference><Citation>Klein F. Risikofaktor Komorbidit&#xe4;ten bei COVID-19- Erkrankung. Pneumologie. 2020;74:640.</Citation></Reference><Reference><Citation>Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:e212-3.</Citation></Reference><Reference><Citation>Daneshgaran G, Dubin DP, Gould DJ. Cutaneous manifestations of COVID-19: an evidence-based review. Am J Clin Dermatol. 2020;21:627-39.</Citation></Reference><Reference><Citation>Sameni F, Hajikhani B, Yaslianifard S, Goudarzi M, Owlia P, Nasiri MJ, et al. COVID-19 and skin manifestations: an overview of case reports/case series and meta-analysis of prevalence studies. Front Med. 2020;7:1-14.</Citation></Reference><Reference><Citation>Kuriyama Y, Shimizu A, Oka H, Sato M, Makioka K, Ikota H, et al. Erythema nodosum-like eruption in coronavirus disease 2019: a case report and literature review of Asian countries. J Dermatol. 2021;48:1588-92.</Citation></Reference><Reference><Citation>Tamai M, Sakamoto R, Goto N, Morimura O, Nishida T, Iwahashi H, et al. Cutaneous manifestations of coronavirus disease 2019 patients in Japan. J Dermatol. 2022;49:872-8.</Citation></Reference><Reference><Citation>Giavedoni P, Podlipnik S, Peric&#xe0;s JM, Fuertes de Vega I, Garc&#xed;a-Herrera A, Al&#xf3;s L, et al. Clinical medicine skin manifestations in COVID-19: prevalence and relationship with disease severity. J Clin Med. 2020;9:3261.</Citation></Reference><Reference><Citation>Gehlhausen JR, Little AJ, Ko CJ, Emmenegger M, Lucas C, Wong P, et al. Lack of association between pandemic chilblains and SARS-CoV-2 infection. Proc Natl Acad Sci USA. 2022;119:e2122090119.</Citation></Reference><Reference><Citation>Mart&#xed;n Carreras-Presas C, Amaro S&#xe1;nchez J, L&#xf3;pez-S&#xe1;nchez AF, Jan&#xe9;-Salas E, Somacarrera P&#xe9;rez ML. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2021;27(S3):710-2.</Citation></Reference><Reference><Citation>Furukawa F, Makino T, Torai R, Mori S, Terada Y, Seki T, et al. Effectiveness of combined bexarotene and excimer laser treatment for folliculotropic mycosis fungoides. Eur J Dermatol. 2021;31:567-8.</Citation></Reference><Reference><Citation>Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases AT A GLANCE COMMENTARY Background. Transl Res. 2020;220:1-13.</Citation></Reference><Reference><Citation>de Perosanz-Lobo D, Fernandez-Nieto D, Burgos-Blasco P, Selda-Enriquez G, Carretero I, Moreno C, et al. Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom? J Eur Acad Dermatol Venereol. 2020;34:e244-5.</Citation></Reference><Reference><Citation>Criado PR, Criado RFJ, Gianotti R, Abdalla BAZ, Pincelli TPH, Michalany AO, et al. Urticarial vasculitis revealing immunolabelled nucleocapsid protein of SARS-CoV-2 in two Brazilian asymptomatic patients: the tip of the COVID-19 hidden iceberg? J Eur Acad Dermatol Venereol. 2021;35:e563-6.</Citation></Reference><Reference><Citation>Bhavsar A, Lonnet G, Wang C, Chatzikonstantinidou K, Parikh R, Brabant Y, et al. Increased risk of herpes zoster in adults &#x2265;50&#x2009;years old diagnosed with COVID-19 in the United States. Open Forum Infect Dis. 2022;9:ofac118.</Citation></Reference><Reference><Citation>Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020;7:ofaa507.</Citation></Reference><Reference><Citation>Xue X, Mi Z, Wang Z, Pang Z, Liu H, Zhang F. High expression of ACE2 on keratinocytes reveals skin as a potential target for SARS-CoV-2. J Invest Dermatol. 2021;141:206-9.e1.</Citation></Reference><Reference><Citation>Magro C, Nuovo G, Mulvey JJ, Laurence J, Harp J, Crowson AN. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clin Dermatol. 2021;39:934-65.</Citation></Reference><Reference><Citation>Hubiche T, Cardot-Leccia N, Florence LD, Seitz-Polski B, Giordana P, le Duff F, et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic supplemental content. JAMA Dermatol. 2021;157:202-6.</Citation></Reference><Reference><Citation>Damsky W, Peterson D, King B. When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection. J Am Acad Dermatol. 2020;83:e269-70.</Citation></Reference><Reference><Citation>Catal&#xe0; A, Mu&#xf1;oz-Santos C, Galv&#xe1;n-Casas C, Roncero Riesco M, Revilla Nebreda D, Sol&#xe1;-Truyols A, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases*. Br J Dermatol. 2022;186:142-52.</Citation></Reference><Reference><Citation>Gambichler T, Boms S, Susok L, Dickel H, Finis C, Abu Rached N, et al. Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatology Venereol. 2022;36:172-80.</Citation></Reference><Reference><Citation>Cabanillas B, Novak N. Allergy to COVID-19 vaccines: a current update. Allergol Int. 2021;70:313-8.</Citation></Reference><Reference><Citation>Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325:1101-2.</Citation></Reference><Reference><Citation>Nelson EJ, McKune SL, Ryan KA, Lednicky JA, Crowe SR, Myers PD, et al. SARS-CoV-2 positivity on or after 9&#x2009;days among quarantined student contacts of confirmed cases. JAMA. 2021;325:1561-2.</Citation></Reference><Reference><Citation>Stone CA Jr, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7:1533-40.e8.</Citation></Reference><Reference><Citation>Erdeljic Turk V. Anaphylaxis associated with the mRNA COVID-19 vaccines: approach to allergy investigation. Clin Immunol. 2021;227:108748.</Citation></Reference><Reference><Citation>Jedlowski PM, Jedlowski MF. Morbilliform rash after administration of pfizer-biontech covid-19 mrna vaccine. Dermatol Online J. 2021;27:13030/qt4xs486zg.</Citation></Reference><Reference><Citation>Niebel D, Ralser-Isselstein V, Jaschke K, Braegelmann C, Bieber T, Wenzel J. Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine. Dermatol Ther. 2021;34:3-5.</Citation></Reference><Reference><Citation>Tomayko MM, Damsky W, Fathy R, McMahon DE, Turner N, Valentin MN, et al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. J Allergy Clin Immunol. 2021;148:750-1.</Citation></Reference><Reference><Citation>Since January 2020 Elsevier has created a COVID-19 resource Centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information. 2020.</Citation></Reference><Reference><Citation>Cebeci F, Kartal I. Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results. Eur J Hosp Pharm. 2021. https://doi.org/10.1136/ejhpharm-2021-002794</Citation></Reference><Reference><Citation>Lam M, Egail M, Bedlow AJ, Tso S. Ribonucleic acid COVID-19 vaccine-associated cutaneous adverse drug events: a case series of two patients. Clin Exp Dermatol. 2021;46:1131-4.</Citation></Reference><Reference><Citation>Pamuk&#xe7;u B. Inflammation and thrombosis in patients with COVID-19: a prothrombotic and inflammatory disease caused by SARS coronavirus-2. Anatol J Cardiol. 2020;24:224-34.</Citation></Reference><Reference><Citation>McGonagle D, De Marco G, Bridgewood C. Mechanisms of Immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun. 2021;121:102662.</Citation></Reference><Reference><Citation>Welsh KJ, Baumblatt J, Chege W, Goud R, Nair N. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the vaccine adverse event reporting system (VAERS). Vaccine. 2021;39:3329-32.</Citation></Reference><Reference><Citation>Abdelmaksoud A, Wollina U, Temiz SA, Hasan A. SARS-CoV-2 vaccination-induced cutaneous vasculitis: report of two new cases and literature review. Dermatol Ther. 2022;35:1-8.</Citation></Reference><Reference><Citation>Gambichler T, Reuther J, St&#xfc;cker M, Stranzenbach R, Torres-Reyes C, Schlottmann R, et al. SARS-CoV-2 spike protein is present in both endothelial and eccrine cells of a chilblain-like skin lesion. J Eur Acad Dermatology Venereol. 2021;35:e187-9.</Citation></Reference><Reference><Citation>Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus-6, &#x2212;7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol. 2021;93:1850-1.</Citation></Reference><Reference><Citation>Arora P, Sardana K, Mathachan SR, Malhotra P. Herpes zoster after inactivated COVID-19 vaccine: a cutaneous adverse effect of the vaccine. J Cosmet Dermatol. 2021;20:3389.</Citation></Reference><Reference><Citation>Eid E, Abdullah L, Kurban M, Abbas O. Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol. 2021;93:5231-2.</Citation></Reference><Reference><Citation>Bostan E, Yalici-Armagan B. Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence? J Cosmet Dermatol. 2021;20:1566-7.</Citation></Reference><Reference><Citation>Walter R, Hartmann K, Fleisch F, Reinhart WH, Kuhn M. Reactivation of herpesvirus infections after vaccinations? Lancet. 1999;353:810.</Citation></Reference><Reference><Citation>Shors AR. Herpes zoster and severe acute herpetic neuralgia as a complication of COVID-19 infection. JAAD Case Reports. 2020;6:656-7.</Citation></Reference><Reference><Citation>Elsaie ML, Youssef EA, Nada HA. Herpes zoster might be an indicator for latent COVID 19 infection. Dermatol Ther. 2020;33:e13666.</Citation></Reference><Reference><Citation>Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17:541-3.</Citation></Reference><Reference><Citation>Rodr&#xed;guez-Jim&#xe9;nez P, Chicharro P, Cabrera LM, Segu&#xed; M, Morales-Caballero &#xc1;, Llamas-Velasco M, et al. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Rep. 2021;12:58-9.</Citation></Reference><Reference><Citation>Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a Nationwide setting. N Engl J Med. 2021;385:1078-90.</Citation></Reference><Reference><Citation>Scollan ME, Breneman A, Kinariwalla N, Soliman Y, Youssef S, Bordone LA, et al. Alopecia areata after SARS-CoV-2 vaccination. JAAD Case Rep. 2022;20:1-5.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636820</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2796</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of internal medicine</Title><ISOAbbreviation>J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Regarding: The long and winding road of COVID-19 in survivors of hospitalization.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/joim.13604</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jolobe</LastName><ForeName>Oscar M P</ForeName><Initials>OMP</Initials><Identifier Source="ORCID">0000-0002-6776-2734</Identifier><AffiliationInfo><Affiliation>British Medical Association, BMA House, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Intern Med</MedlineTA><NlmUniqueID>8904841</NlmUniqueID><ISSNLinking>0954-6820</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636820</ArticleId><ArticleId IdType="doi">10.1111/joim.13604</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Dias MB, Medeiros AP, de Melo SS, Fonseca CS, Jacob-Filho W, Avelino-Silva TJ, et&#xa0;al. The long and winding road of COVID-19 in survivors of hospitalisation: symptoms trajectory and predictors of long COVID. J Intern Med. 2022;293:264-8. https://doi.org/10.1111/joim.13583.</Citation></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and risk of post-acute sequelae of COVID-19. medRxiv preprint posted November 5, 2022. https://doi.org/10.1101/2022.11.03.22281783</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Ardner A, Abreu P, Bao W, Wisemandle W, et&#xa0;al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397-408.</Citation></Reference><Reference><Citation>Swank Z, Senussi Y, Alter G, Walt DR. Persistent circulating SARS-2-CoV-2 spike is associated with post-acute COVID-19. sequelae medRxiv preprint posted June 16, 2022. https://doi.org/10.1101/2022.06.12.22276401.</Citation></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, et&#xa0;al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021;591:639-44.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36636817</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1472-1465</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association between SARS-CoV-2 infection and self-harm: Danish nationwide register-based cohort study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>8</EndPage><MedlinePgn>1-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1192/bjp.2022.194</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Case studies have linked SARS-CoV-2 infection to suicidal behaviour. However, conclusive evidence is lacking.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To examine whether a history of SARS-CoV-2 infection or SARS-CoV-2-related hospital admission was associated with self-harm in the general population and in high-risk groups.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A cohort design was applied to nationwide data on all people aged &#x2265;15 years and living in Denmark between 27 February 2020 and 15 October 2021. Exposure was identified as having had a positive SARS-CoV-2 PCR test, and further assessed as SARS-CoV-2-related hospital admission. Rates of probable self-harm were examined using adjusted incidence rate ratios (aIRRs). The following subgroups were identified: (a) lower educational level, (b) chronic medical conditions, (c) disability pension, (d) mental disorders, (e) substance use disorders, and history of (f) homelessness and (g) imprisonment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 4 412 248 included individuals, 260 663 (5.9%) had tested positive for SARS-CoV-2. Out of 5453 individuals presenting with self-harm, 131 (2.4%) had been infected. Individuals with a history of a positive SARS-CoV-2 test result had an aIRR for self-harm of 0.86 (95% CI 0.72-1.03) compared with those without. High rates were found after a SARS-CoV-2-related hospital admission (aIRR = 7.68; 95% CI 5.61-10.51) or a non-SARS-CoV-2-related admission (aIRR = 10.27; 95% CI 9.65-10.93) versus non-infected and not admitted. In sensitivity analyses with a more restrictive definition of self-harm, a positive PCR test was associated with lower rates of self-harm.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Individuals with a PCR-confirmed SARS-CoV-2 infection did not have higher rates of self-harm than those without. Hospital admission in general, rather than being SARS-CoV-2 positive. seemed to be linked to elevated rates of self-harm.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erlangsen</LastName><ForeName>Annette</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3475-0558</Identifier><AffiliationInfo><Affiliation>Danish Research Institute for Suicide Prevention, Mental Health Centre Copenhagen, Copenhagen, Denmark; Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen, Denmark; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; and Center of Mental Health Research, Australian National University, Canberra, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Ping</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6741-6228</Identifier><AffiliationInfo><Affiliation>National Center for Suicide Research and Prevention, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Trine</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4918-5862</Identifier><AffiliationInfo><Affiliation>Danish Research Institute for Suicide Prevention, Mental Health Centre Copenhagen, Copenhagen, Denmark; Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen, Denmark; and Section of Epidemiology, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawton</LastName><ForeName>Keith</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-4985-5715</Identifier><AffiliationInfo><Affiliation>Centre for Suicide Research, University of Oxford, Oxford, UK; and Oxford Health NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osler</LastName><ForeName>Merete</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6921-220X</Identifier><AffiliationInfo><Affiliation>Center for Clinical Research and Prevention, Bispebjerg &amp; Frederiksberg Hospitals, Copenhagen, Denmark; and Section of Epidemiology, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hjorth&#xf8;j</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6943-4785</Identifier><AffiliationInfo><Affiliation>Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen University Hospital, Hellerup, Denmark; and Section of Epidemiology, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benros</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-4939-9465</Identifier><AffiliationInfo><Affiliation>Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen, Denmark; and Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ethelberg</LastName><ForeName>Steen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9709-356X</Identifier><AffiliationInfo><Affiliation>Infectious Disease Epidemiology &amp; Prevention, Statens Serum Institut, Copenhagen, Denmark; and Department of Global Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;lbak</LastName><ForeName>K&#xe5;re</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Epidemiological Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark; and Department of Veterinary and Animal Science, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laursen</LastName><ForeName>Thomas Munk</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0001-6934-1784</Identifier><AffiliationInfo><Affiliation>National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordentoft</LastName><ForeName>Merete</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Danish Research Institute for Suicide Prevention, Mental Health Centre Copenhagen, Copenhagen, Denmark; Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen, Denmark; and Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Sandra Feodor</ForeName><Initials>SF</Initials><Identifier Source="ORCID">0000-0002-7598-5014</Identifier><AffiliationInfo><Affiliation>Copenhagen Research Center for Mental Health, Mental Health Centre Copenhagen, Copenhagen University Hospital, Hellerup, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Suicide attempt</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">self-harm</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36636817</ArticleId><ArticleId IdType="doi">10.1192/bjp.2022.194</ArticleId><ArticleId IdType="pii">S0007125022001945</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>